Abstract:BACKGROUND: Vascular endothelial growth factor (VEGF) can specifically promote the division and proliferation of endothelial cells and the revascularization, finally induce angiopoiesis. Recently, VEGF-based gene therapy has been gradually used in clinical trials, but some limits on usually used vectors deserve further studies, including the low transfection efficiency of plasmid vector, the immunogenicity of adnovirus vector to host cells and the potential risk of infection. OBJECTIVE: To construct the non-pathogenic recombinant adeno-associated vires (AAV) co-expressing human vascular endethelial growth factor 165 (hVEGF165) and green fluorescent protein (GFP) label and measure the virus titer and assess its biological activity.DESIGN, TIME AND SETTING: The open experiment was performed at the Vitrus Laboratory of Shanxi Provincial Center for Disease Control and Prevention from March to September 2007.MATERIALS: AAV-293 virus packaging cell line, AAV HT-1080 cells were purchased from Swatagene, USA. E.coli DH5α was a stocked strain from Shanxi Provincial Center for Disease Control and Prevention. AAV Helper Free System (pAAV-IRES-GFP vector containing GFP label) was purchased from Stratagene, USA. Plasmid pUC18-hVEGF165 was constructed previously by Dr.Shi from Department of Orthopaedics of Second Affiliated Hospital of Xi'an Jiaotong University.METHODS: The hVEGF165 gone from plasmid pUC18-hVEGF165 was amplified and inserted into plasmid pAAV-IRES-hrGFP. Then recombinant plasmid pAAV-hVEGF165-IRES-hrGFP, pAAV-RC and pAAV-Helper were co-transfected into AAV-293 cells to complete rAAV-hVEGF165-IRES-hrGFP packaging through homologous recombination. The efficiency of A.AV packaging was monitored under a fluorescent microscope, and the recombinant viral particles were harvested from infected AAV-293 cells and further concentrated and purified. The recombinant virus infected the AAV-HT1080 cells, the virus titer was measured by fluorescence counting, and the recombinant AAV-hVEGF165-IRES-hrGFP was verified by the amplification of the exogenous gene of hVEGF165 from virus genome.MAIN OUTCOME MEASURES: Virus packaging efficiency was monitored under the fluorescence microscope. Virus filer was measured by fluorescent counting. The packaging of recombinant virus was determined by the amplification of the exogenous hVEGF165 gene.RESULTS: The amplified products were verified as hVEGF165 gene by DNA sequencing, and the recombinant pAAV-hVEGF165-IRES-hrGFP was confirmed by double digestion. The system provided a high packaging ratio of over 95% and the purified recombinant virus had a high titer of 5.5×1011 vp/mL. The recombinant virus was confirmed by exogenous human VEGF165 gene from virus genome.CONCLUSION: The non-pathogenic rAAV-hVEGF165-GFP simultaneously carrying hVEGF165 and GFP 1abel is successfully constructed, with a high titer and satisfying biological activity.

A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

558. Second Generation Vaccinia Carrier for Scalable and Efficient Production of Recombinant AAV Vectors

Establishment of a High-Yield Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System Independent of Bocavirus Nonstructural Proteins

Advanced biomanufacturing and evaluation of adeno-associated virus

[A Novel Packaging System of Recombinant AAV5/5 Vector].

[Large-Scale Production of Recombinant Adeno-Associated Virus (Raav)].

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Process Improvement of Adeno-Associated Virus Production

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector

High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus

A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

AAV Production Everywhere: A Simple, Fast, and Reliable Protocol for In‐house AAV Vector Production Based on Chloroform Extraction

Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Construction and Identification of Recombinant Adeno- Associated Virus Vector Co-Expressing Human Vascular Endothelial Growth Factor and Green Fluorescent Protein

Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells

Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII Delivery.

Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells.